Cardiol Therapeutics Inc. submitted Form 6-K to report compliance with SEC requirements, including an incorporation of a legal consent from July 16, 2024. This event is categorized under 'Other Special Situation' and carries a neutral sentiment as it shares no significant impact on the company's equity from an investor perspective.